FDA Inspection 1230049 — Novitium Pharma LLC

Novitium Pharma LLC — FEI 3012541241

The FDA completed an inspection of Novitium Pharma LLC on Feb 16, 2024 in East Windsor, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Feb 16, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
East Windsor, NJ (United States)

Additional details

Postmarket Adverse Drug Experience (PADE)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.